SYNAGIS스(팔리비주맙)는 재조합 DNA 기술로 생산된 인간화 모노클로널 항체(IgG1к)로 RSV의 F단백질 A항원 부위의 에피토프를 지향하는 항체입니다. 팔리비주맙은 인간 항체(95%)와 마우스 항체(5%)의 복합 항체입니다. 인간 중쇄 서열은 인간 IgG1의 정상 도메인 및 VH 유전자 Cor와 Cess의 가변 프레임워크 영역에서 유래합니다. 인간 경쇄 서열은 Cк의 정상 도메인 및 VL 유전자 K104의 가변 프레임워크 영역과 Jк-4에서 유래합니다. 마우스 서열은 마우스 단클론 항체 Mab 1129에서 상보성 결정 영역을 인간 항체 프레임워크에 이식하는 과정을 통해 얻어졌습니다. 팔리비주맙은 두 개의 중쇄와 경쇄로 구성되어 있으며, 분자량은 약 148,000Da입니다. Synergis는 무균 무방부제 액상 제제로서 근육 주사로 1mL당 100mg을 투여합니다. Synergis의 생산에는 티메로살 및 기타 수은 함유 염은 사용되지 않습니다. 용액의 pH는 6.0이며 투명하거나 약간 불투명합니다. 시너시스 액 100mg 1회용 바이알 1ml에는 파리비주맙 100mg 외에 염화물(0.5mg), 글리신(0.1mg), 히스티딘(3.9mg)이 함유되어 있습니다. Synergis 액상 50mg 1회용 바이알에는 팔리비주맙 50mg, 0.5mL 용량에 염화물(0.2mg), 글리신(0.06mg), 히스티딘(1.9mg)이 함유되어 있습니다.
주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 호흡기세포융합바이러스(RSV)용 SYNAGIS에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.
"SYNAGIS Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about SYNAGIS for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the SYNAGIS for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SYNAGIS for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SYNAGIS market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
SYNAGIS (Palivizumab) is a humanized monoclonal antibody (IgG1к) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cк and the variable framework regions of the VL gene K104 with Jк-4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved grafting the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy and light chains and has a molecular weight of approximately 148,000 Da. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. Thimerosal or other mercury-containing salts are not used in the production of SYNAGIS. The solution has a pH of 6.0 and should appear clear or slightly opalescent. Each 100 mg single-dose vial of SYNAGIS liquid solution contains 100 mg of palivizumab and also contains chloride (0.5 mg), glycine (0.1 mg), and histidine (3.9 mg) in a volume of 1 mL. Each 50 mg single-dose vial of SYNAGIS liquid solution contains 50 mg of palivizumab and also contains chloride (0.2 mg), glycine (0.06 mg), and histidine (1.9 mg), in a volume of 0.5 ml.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SYNAGIS Analytical Perspective by DelveInsight
This report provides a detailed market assessment of SYNAGIS for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of SYNAGIS for RSV covering trial interventions, trial conditions, trial status, start and completion dates.